We thank Professors Celik and Iyisoy for their comments on the Candesartan in the
Prevention of Relapsing Atrial Fibrillation (CAPRAF) study [1]. This was the first double blind …

BACKGROUND: Several studies have indicated that treatment with angiotensin converting
enzyme (ACE) inhibitors and angiotensin II type 1 receptor blockers (ARBs) may reduce the …

How angiotensin inhibition might protect against AF is not completely known. There is a
plausible scientific basis for the notion that inhibition of the renin-angiotensin system can …

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers Did you know that your browser is out of date? To get the best experience …

Prevention of atrial fibrillation (AF) recurrence with anti-arrhythmic agents is generally
limited. Experimental studies suggest that angiotensin II receptor blockers (ARBs) can …

BACKGROUND: Atrial fibrillation is the most common cardiac arrhythmia, and no current
therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II …

Background Antiarrhythmic agents have modest efficacy in preventing atrial fibrillation (AF)
recurrence. Although retrospective analyses have suggested a preventive effect of inhibitors …

Background: Controversy persists regarding the efficacy of angiotensin converting enzyme
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in the prevention of recurrent …

Background The possibility of preventing atrial fibrillation recurrence with anti-arrhythmic
agents is very limited, given the discouraging results obtained with current drugs in many …

Atrial fibrillation (AF) is a common arrhythmia associated with increased risk of stroke and
mortality. The early appearance of electrical remodeling is followed by structural remodeling …